Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Oct;137(4):749-53.

Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy

Affiliations

Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy

J Arnoldi et al. Am J Pathol. 1990 Oct.

Abstract

The aim of this study was to determine cytokines in human leprosy lesions by means of immunohistologic examination. Cryostat sections of skin biopsies from 57 patients with various forms of leprosy were immunostained according to the APAAP method, using monoclonal antibodies against interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), and, in addition, against CD 1 antigen. Granulomas in biopsies of untreated patients with tuberculoid leprosy showed large amounts of cells positive for IL-1 beta, TNF-alpha, IFN-gamma, and CD 1, whereas no positive signals could be detected in untreated patients with lepromatous leprosy. However, in those biopsies obtained from lepromatous leprosy patients undergoing chemotherapy, positive staining for cytokines as well as subepidermal Langerhans cells increased to a detectable amount. Remarkably, in tuberculoid leprosy patients, the number of IL-1 beta--positive cells did not vary under therapy, while the number of TNF-alpha and IFN-gamma reactive cells decreased. These results suggest that immunohistologic determination of cytokines in combination with the assessment of subepidermal Langerhans cells in human leprosy lesions may be used as a parameter for the patient's status of cell-mediated immunity under chemotherapeutic treatment.

PubMed Disclaimer

References

    1. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255-73 - PubMed
    1. Scand J Immunol. 1989 Nov;30(5):549-62 - PubMed
    1. Lab Invest. 1981 Nov;45(5):465-8 - PubMed
    1. Int J Cancer. 1983 Jan 15;31(1):13-20 - PubMed
    1. J Exp Med. 1983 Dec 1;158(6):2165-70 - PubMed

Publication types

LinkOut - more resources